Form 4: David E. Lazar Acquires Additional Convertible Preferred Stock in Cyclacel Pharmaceuticals

David E. Lazar, Interim CEO and 10% Owner of Cyclacel Pharmaceuticals, acquires Series D Convertible Preferred Stock for $2.1 million, convertible into 231 million shares of common stock.

Summary

• David E. Lazar, Interim CEO and 10% Owner of Cyclacel Pharmaceuticals, acquired additional shares of convertible preferred stock.
• On January 6, 2025, Lazar acquired 1,000,000 shares of Series C Convertible Preferred Stock at $1.00 per share for a total of $1,000,000.
• Each share of Series C Preferred Stock is convertible into 2.65 shares of common stock.
• On February 6, 2025, Lazar acquired 2,100,000 shares of Series D Convertible Preferred Stock at $1.00 per share for a total of $2,100,000.
• Each share of Series D Preferred Stock is convertible into 110 shares of common stock.
• Both Series C and Series D Preferred Stock are perpetual and have no expiration date.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the insider purchase is a good sign, the potential dilution from conversion tempers the enthusiasm.

Positives

• The investment by David E. Lazar demonstrates confidence in Cyclacel Pharmaceuticals.
• The capital injection of $3.1 million ($1 million for Series C and $2.1 million for Series D) strengthens the company's financial position.

Negatives

• Potential dilution of existing shareholders if the preferred stock is converted into common stock.

Risks

• The conversion of preferred stock could significantly increase the number of outstanding common shares, potentially diluting existing shareholders.
• The company's performance will need to justify the confidence shown by the insider investment.

Future Outlook

The document does not contain specific forward-looking statements beyond the details of the stock acquisition and conversion rights.

Industry Context

Insider purchases can often be seen as a positive signal, indicating management's belief in the company's future prospects. However, the potential dilution effect needs to be considered.

Stakeholder Impact

• Shareholders may experience dilution if the preferred stock is converted to common stock.
• The company benefits from the capital injection.

Key Dates

Keywords

Cyclacel Pharmaceuticals, Convertible Preferred Stock, Insider Trading, Form 4, David E. Lazar, CYCC